Myocardial remodeling in low-renin hypertension: Molecular pathways to cellular injury in relative aldosteronism

被引:0
|
作者
Syamal K. Bhattacharya
Malay S. Gandhi
German Kamalov
Robert A. Ahokas
Yao Sun
Ivan C. Gerling
Karl T. Weber
机构
[1] University of Tennessee Health Science Center,Division of Cardiovascular Diseases
来源
关键词
Plasma Aldosterone; Hypertensive Heart Disease; Myocardial Remodel; Intracellular Zinc; Calcium Paradox;
D O I
暂无
中图分类号
学科分类号
摘要
The pathologic hypertrophy of hypertensive heart disease is related to the quality, not the quantity, of myocardium; the presence of fibrosis is inevitably linked to structural and functional insufficiencies with increased cardiovascular risk. Elevations in plasma aldosterone that are inappropriate relative to dietary sodium, or relative aldosteronism, are accompanied by suppressed plasma renin activity, elevation in arterial pressure, and dyshomeostasis of divalent cations. The accompanying hypocalcemia, hypomagnesemia, and hypozincemia of aldosteronism contribute to the appearance of secondary hyperparathyroidism. Parathyroid hormone-mediated intracellular calcium overloading of cardiac myocytes and mitochondria leads to the induction of oxidative stress and molecular pathways associated with cardiomyocyte necrosis and scarring of myocardium, whereas the dyshomeostasis of zinc compromises antioxidant defenses. This dyshomeostasis of calcium and zinc, intrinsically coupling prooxidant calcium and antioxidant zinc, raises the prospect for therapeutic strategies designed to mitigate intracellular calcium overloading while enhancing zinc-mediated antioxidant defenses, thus preventing adverse myocardial remodeling with fibrosis, associated diastolic dysfunction, and cardiac arrhythmias.
引用
收藏
页码:412 / 420
页数:8
相关论文
共 50 条
  • [31] Diagnostic approach to low-renin hypertension
    Monticone, Silvia
    Losano, Isabel
    Tetti, Martina
    Buffolo, Fabrizio
    Veglio, Franco
    Mulatero, Paolo
    CLINICAL ENDOCRINOLOGY, 2018, 89 (04) : 385 - 396
  • [32] Monogenic forms of low-renin hypertension
    Garovic, Vesna D.
    Hilliard, Anthony A.
    Turner, Stephen T.
    NATURE CLINICAL PRACTICE NEPHROLOGY, 2006, 2 (11): : 624 - 630
  • [33] HEMODYNAMIC CHARACTERISTICS OF LOW-RENIN HYPERTENSION
    SCHALEKAMP, MADH
    BIRKENHAGER, WH
    ZAAL, GA
    KOLSTERS, G
    CLINICAL SCIENCE AND MOLECULAR MEDICINE, 1977, 52 (04): : 405 - 412
  • [34] Diagnosis and treatment of low-renin hypertension
    Mulatero, Paolo
    Verhovez, Andrea
    Morello, Fulvio
    Veglio, Franco
    CLINICAL ENDOCRINOLOGY, 2007, 67 (03) : 324 - 334
  • [35] ALDOSTERONE IN LOW-RENIN ESSENTIAL HYPERTENSION
    BROWN, RD
    CLINICAL RESEARCH, 1975, 23 (03): : A234 - A234
  • [36] ADRENAL MORPHOLOGY IN LOW-RENIN HYPERTENSION
    LONGO, D
    ESTERLY, JA
    KEITZER, FW
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1974, 62 (01) : 148 - 148
  • [37] Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone
    Ori, Yaacov
    Chagnac, Avry
    Korzets, Asher
    Zingerman, Boris
    Herman-Edelstein, Michal
    Bergman, Michael
    Gafter, Uzi
    Salman, Hertzel
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 (07) : 1787 - 1793
  • [38] Bimodal Aldosterone Distribution in Low-Renin Hypertension
    Adlin, E. Victor
    Braitman, Leonard E.
    Vasan, Ramachandran S.
    AMERICAN JOURNAL OF HYPERTENSION, 2013, 26 (09) : 1076 - 1085
  • [39] LOW-RENIN HYPERTENSION - OCCURRENCE IN VASCULAR COMPLICATIONS
    GULATI, SC
    CHANNICK, BJ
    ADLIN, EV
    BIDDLE, CM
    MARKS, AD
    ARCHIVES OF INTERNAL MEDICINE, 1975, 135 (02) : 260 - 263
  • [40] ENALAPRIL IN LOW-RENIN ESSENTIAL-HYPERTENSION
    WILKINS, LH
    DUSTAN, HP
    WALKER, JF
    OPARIL, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 34 (03) : 297 - 302